clemizole
Small moleculeexperimental
Clemizole, sold under the brand names Allercur and Histacur, is a histamine H1 receptor antagonist of the benzimidazole group described as an antihistamine, antipruritic, and sedative which is no longer marketed. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 29, 2019 (NCT04069689)
Timeline
Indications
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaClemizole ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05066217 | Phase 2 | Feb 1, 2022 | Epygenix Therapeutics, Inc. |
| NCT04462770 | Phase 2 | Sep 30, 2020 | Epygenix Therapeutics, Inc., Greenlight Clinical |
| NCT04069689 | Phase 1 | Aug 29, 2019 | Epygenix Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Epygenix Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2019 |
| Greenlight Clinical | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1